Phase IVEnrolling Remote Available

Continuous Glucose Monitoring vs Standard Care in Elderly Type 2 Diabetes Patients

Dexcom·NCT05198765·Type 2 Diabetes

Duration

6 months

Cost

Free to Patients

Phase

Phase IV

Closes

Nov 2025

About This Trial

Assessing whether continuous glucose monitoring improves outcomes and reduces hypoglycemia in elderly T2D patients.

Multiple US Sites

Remote participation available, some or all visits can be done from home.

Condition focus: Type 2 Diabetes

Available in: US

All study medications and visits are provided at no cost to participants

Your health data is protected under HIPAA / GDPR / UAE PDPL regulations

You may withdraw from the trial at any time without penalty

Specific eligibility criteria (age ranges, lab values, prior medications) will be confirmed by the study coordinator after you express interest.

Trial Summary

NCT NumberNCT05198765

SponsorDexcom

PhasePhase IV

Duration6 months

ClosesNov 2025

ConditionType 2 Diabetes

Phase IIIType 2 Diabetes✓ PAG Endorsed

National Institute of Diabetes

Comparing a structured low-carbohydrate eating plan to standard dietary guidelines for blood sugar management.

18 monthsChicago, IL$0

Phase IIIType 2 DiabetesRemote

Eli Lilly UAE

Head-to-head comparison of tirzepatide and insulin glargine in UAE adults with poorly controlled T2D.

12 monthsDubai, UAE$045 spots left

95% match

NCT05401245